ArticleUnited European gastroenterology journal2023
Transmural remission improves clinical outcomes up to 5 years in Crohn's disease.
Article in United European gastroenterology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Assessment of transmural treatment response in known Crohn's disease: a prospective blinded study of the intermodality agreement between intestinal ultrasound and magnetic resonance enterography.BMJ open gastroenterology · 2026Trial
- Early transmural response assessed by intestinal ultrasound predicts long-term clinical remission in patients with IBD: Results from the TRUST BEYOND study.Inflammatory bowel diseases · 2026Article
- Magnetic Resonance Enterography Predicts Long-Term Outcomes in Crohn's Disease: A Systematic Review and Meta-Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Treat-to-Target in Inflammatory Bowel Disease: An Updated Survey of Treatment Strategies among Portuguese Gastroenterologists.GE Portuguese journal of gastroenterology · 2025Article
- Gastroenterologists' attitudes and challenges toward treat-to-target strategies in inflammatory bowel disease: a multinational survey.Therapeutic advances in gastroenterology · 2025Article
- The degree of bowel remission predicts phenotype progression in Crohn's disease.United European gastroenterology journal · 2024Article
- Reporting of Magnetic Resonance Enterography in Inflammatory Bowel Disease: Results of an Italian Survey.Journal of clinical medicine · 2024Article
- Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn's disease: a case-control study.International journal of colorectal disease · 2024Article
- Treatment endpoints in ulcerative colitis: Does one size fit all?World journal of gastrointestinal pharmacology and therapeutics · 2024Article
- Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease.United European gastroenterology journal · 2024Article
- Advancing transmural remission as a treatment target in Crohn's disease: The future of tight-control strategy?United European gastroenterology journal · 2023Article
- Transmural remission improves clinical outcomes up to 5 years in Crohn's disease.United European gastroenterology journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvidence supporting transmural remission (TR) as a long-term treatment target in Crohn's disease (CD) is still unavailable. Less stringent but more reachable targets such as isolated endoscopic (IER) or radiologic remission (IRR) may also be acceptable options in the long-term.
methodsMulticenter retrospective study including 404 CD patients evaluated by magnetic resonance enterography and colonoscopy. Five-year rates of hospitalization, surgery, use of steroids, and treatment escalation were compared between patients with TR, IER, IRR, and no remission (NR).
results20.8% of CD patients presented TR, 23.3% IER, 13.6% IRR and 42.3% NR. TR was associated with lower risk of hospitalization (odds-ratio [OR] 0.244 [0.111-0.538], p < 0.001), surgery (OR 0.132 [0.030-0.585], p = 0.008), steroid use (OR 0.283 [0.159-0.505], p < 0.001), and treatment escalation (OR 0.088 [0.044-0.176], p < 0.001) compared to no NR. IRR resulted in lower risk of hospitalization (OR 0.333 [0.143-0.777], p = 0.011) and treatment escalation (OR 0.260 [0.125-0.540], p < 0.001), while IER reduced the risk of steroid use (OR 0.442 [0.262-0.745], p = 0.002) and treatment escalation (OR 0.490 [0.259-0.925], p = 0.028) compared to NR.
conclusionsTR improved clinical outcomes over 5 years of follow-up in CD patients. Distinct but significant benefits were seen with IER and IRR. This suggests that both endoscopic and radiologic remission should be part of the treatment targets of CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.